Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-CoA thioesterase 9 (ACOT9) is a mitochondrial thioesterase enzyme encoded by the ACOT9 gene. It hydrolyzes a broad range of acyl-CoA esters, including short-, medium-, and long-chain species, thereby regulating mitochondrial levels of acyl-CoA, free fatty acids, and CoA[1][2][3][4]. ACOT9 is expressed predominantly in brown adipose tissue and kidney, and is minimally present in liver[2][3][4]. Recent studies show ACOT9 links fatty acid metabolism to amino acid metabolism, acting as a regulatory node affected by mitochondrial NADH and CoA concentrations[2][4]. Its role includes modulation of key metabolic pathways, but clinical or therapeutic drug targeting of ACOT9 has not yet been established. Dysfunction in ACOT9 is associated with lipid metabolism disorders and may impact metabolic homeostasis[6].
Hydrolysis of acyl-CoA esters to generate free fatty acids and CoA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-CoA thioesterase 9 (ACOT9).